Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    17975015 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
Conditions: Smoldering Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Intervention:
2 Active, not recruiting Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
3 Withdrawn Imaging Studies and the Development of Multiple Myeloma
Conditions: Multiple Myeloma;   Smoldering Multiple Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Intervention: Drug: Fluciclatide
4 Completed
Has Results
Imaging in MGUS, SMM and MM
Conditions: Multiple Myeloma;   Smoldering Multiple Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Interventions: Drug: 18-NaF PET;   Other: DCE-MRI;   Drug: 18-FDG PET/CT

Indicates status has not been verified in more than two years